Pfizer to invest $120 million to produce COVID-19 oral treatment in the U.S.

Healthcare professionals can now use Vaxzevria as a third dose booster in patients previously given a primary vaccine schedule of either Vaxzevria or an EU-approved mRNA COVID-19 vaccine.